Abbvie

This study tested a daily pill called upadacitinib in 912 teens and adults with moderate to severe eczema (atopic dermatitis) that was not well controlled with creams. Participants received either the study drug or a placebo for 16 weeks. The main goals were to see if the drug co…

This phase 3 trial tested whether adding the oral drug atogepant (QULIPTA) to standard Botox injections can safely and effectively prevent chronic migraine in adults. 75 participants took atogepant daily for 24 weeks alongside their regular Botox. Researchers monitored side effec…

This study tested whether a daily oral medication called atogepant (brand name Qulipta) can prevent migraines in Japanese adults who have 4 to 14 migraine days per month. Over 500 participants were randomly assigned to receive one of three doses of atogepant or a placebo for 12 w…

This study looks at how safe and effective upadacitinib is for Chinese adolescents and adults with moderate to severe atopic dermatitis (eczema). About 200 participants will take the drug as prescribed by their doctor and be followed for up to 24 months. The goal is to track seri…

This study tested the safety of a new drug, ABBV-951, given as a continuous 24-hour infusion under the skin for people with advanced Parkinson's disease. 118 adults who had completed earlier studies took part. The goal was to see if the drug is safe and tolerable over 96 weeks, w…

This study tested an oral medication called upadacitinib in 912 teenagers and adults with moderate to severe eczema (atopic dermatitis) who needed stronger treatment. Participants received either the drug or a placebo for 16 weeks. The main goals were to see if the drug could sig…

This study is testing the long-term safety of ABBV-951, a drug given as a continuous 24-hour infusion under the skin for people with advanced Parkinson's disease. About 130 adults who completed an earlier study will continue receiving the treatment. Researchers will monitor side …

This study tracked over 2,300 adults in Korea who were prescribed Skyrizi (risankizumab) for moderate to severe plaque psoriasis or psoriatic arthritis. Researchers monitored side effects and symptom changes for 52 weeks during routine doctor visits. The goal was to confirm the d…

This study compares two already-approved drugs, risankizumab (injection) and deucravacitinib (pill), for adults with moderate plaque psoriasis. About 393 participants who haven't used biologics before will receive one of the treatments for up to 44 weeks. The goal is to see which…

This study tested whether a combination of two drugs, venetoclax and azacitidine, can help adults with acute myeloid leukemia (AML) stay in remission after initial chemotherapy. The goal was to find the right dose and see if it safely delays the cancer from coming back. The study…

This study looked at how well upadacitinib, an anti-inflammatory pill, controls pain in people with axial spondylarthritis (axSpA), a condition causing chronic back pain. Over 700 adults from 19 countries took the drug as prescribed by their doctors and were followed for 12 month…

This study tested whether adding the experimental drug navitoclax to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. The main goal was to see if the combination could shrink an enlarged spleen by at le…

This study tested a gel stent implant for open-angle glaucoma, a leading cause of blindness. 74 adults aged 45+ received the implant and were followed for 12 months. The goal was to safely lower eye pressure and reduce the need for glaucoma medications.

This study tested the drug upadacitinib in people with moderate to severe atopic dermatitis (eczema) who also have prurigo nodularis, a condition causing intense itching and hard bumps. The goal was to see if the drug reduces itching and improves skin. The study was observational…

This study tested a daily pill called upadacitinib in 734 adults with axial spondyloarthritis, a type of arthritis that causes pain and stiffness in the spine. The drug was compared to a placebo to see if it could reduce symptoms and control the disease. Results showed that upada…

This study tested the drug upadacitinib (RINVOQ) in 429 people with giant cell arteritis, a condition causing inflamed blood vessels. Participants took the drug or a placebo along with steroids. The goal was to see if upadacitinib helps achieve remission faster and with less ster…

This study tested the drug risankizumab (Skyrizi) in 214 adults with moderate to severe genital or scalp psoriasis. Participants received either the drug or a placebo for 16 weeks, then all received the drug. The goal was to see if it could clear or nearly clear the skin in these…

This study tested the drug RINVOQ in 69 adults with ankylosing spondylitis, a type of arthritis that mainly affects the spine. Participants took RINVOQ as prescribed by their doctor and were followed for up to a year. The goal was to see how safe and effective the drug is in real…

This study looked at how safe and effective upadacitinib is for Korean patients with rheumatoid arthritis, atopic dermatitis, ankylosing spondylitis, or psoriatic arthritis. Over 2,300 adults took the drug as prescribed by their doctor and were followed for about 28 weeks. Resear…

This study tested an experimental drug called elezanumab in people with a recent cervical spinal cord injury. The goal was to see if the drug could improve arm and hand movement and was safe. About 60 adults aged 18-75 with severe neck-level injuries received either the drug or a…

This study tested a drug called navitoclax, either alone or added to the standard drug ruxolitinib, in 191 people with myelofibrosis. The main goal was to see if the treatment could shrink the spleen by at least 35% after 24 weeks. The trial also looked at whether it could reduce…

This completed Phase 1/2a trial tested a gene therapy called RST-001 (AGN-151597) in 14 people with advanced retinitis pigmentosa, a genetic eye disease that causes severe vision loss. All participants had very poor vision (hand motion or worse) at the start. The study aimed to c…

This phase 2 trial tested a drug called mirvetuximab soravtansine in 79 people with recurrent platinum-sensitive ovarian, peritoneal, or fallopian tube cancers that have high levels of a protein called folate receptor-alpha. The drug is given by IV every three weeks. The main goa…

This completed study looked at how safe and effective upadacitinib (RINVOQ) is for Korean adults with moderate to severe ulcerative colitis or Crohn's disease. About 600 participants were followed for up to 52 weeks while taking the drug as prescribed by their doctor. The main go…

This study looked at the long-term safety of the drug linaclotide in children aged 6 to 17 with functional constipation or irritable bowel syndrome with constipation (IBS-C). A total of 381 children who had already completed earlier studies took linaclotide for 24 or 52 weeks. Th…

This study looked at how safe and effective the drug Rinvoq is for adults with moderate to severe ulcerative colitis. About 300 people in Japan took Rinvoq as part of their normal care and were followed for up to 60 weeks. The main goal was to track serious infections and other s…

This study tested an experimental drug called ABBV-668 in 30 adults with moderate to severe ulcerative colitis, a condition that causes inflammation and bleeding in the colon. Participants took the drug twice daily for 16 weeks, and researchers checked for side effects and signs …

This Phase 2 trial tested an experimental drug called elezanumab in 121 people who had an acute ischemic stroke. The goal was to see if it could safely improve neurological function and reduce disability compared to a placebo. Participants received the drug or placebo by IV withi…

This study tested the safety and effectiveness of tavapadon, an experimental drug, in 992 people with Parkinson's disease over 58 weeks. Participants took flexible doses of the medication to see how well it controlled symptoms and what side effects occurred. The goal was to under…

This study tested an experimental drug called ABBV-916 in people with early Alzheimer's disease. Participants received either the drug or a placebo intravenously every 4 weeks for 6 months, with an optional 2-year extension where everyone gets the drug. The goal was to check safe…

This early-phase study tested a new drug called ABBV-155, given alone or with standard chemotherapy (paclitaxel or docetaxel), in 168 adults with advanced solid tumors that had come back or stopped responding to treatment. The main goal was to find a safe dose and check for early…

This study looked at how well the drug Venetoclax works for adults with acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 120 patients in Switzerland and Austria took Venetoclax pills daily as part of their normal care. Researchers tracked …

This study looked at how safe and effective Venetoclax is for people with chronic lymphocytic leukemia (CLL) when used in everyday medical practice. Fourteen patients were followed to track side effects and how well the drug worked. The goal was to monitor real-world use, not to …

This study looks at how safe and effective the oral drug venetoclax (Venclexta) is for adults with acute myeloid leukemia (AML) when used in everyday medical practice. About 150 people in South Korea took the drug as prescribed by their doctor for up to 7 months. Researchers trac…

This Phase 3 trial tested whether tavapadon, a daily pill, can improve movement and daily activities in people with early Parkinson's disease. Over 300 participants took either tavapadon or a placebo for 27 weeks. The study measured changes in motor function and daily living skil…

This registry study followed 156 Chinese patients with moderate to severe Crohn's disease who were prescribed Humira (adalimumab) by their doctors. The goal was to see how safe and effective the drug is in real-world use over one year. Researchers tracked serious side effects and…

This completed study followed 2759 adults with moderate to severe plaque psoriasis to see how well risankizumab works compared to other commonly used biologic drugs. Researchers measured skin clearance and how long patients stayed on treatment. The goal was to understand real-wor…

This study looked at the long-term safety of cariprazine, a medication, in 310 children and teens with schizophrenia, bipolar I disorder, or autism spectrum disorder. Over 52 weeks, researchers monitored side effects, vital signs, lab results, and movement disorders. The goal was…

This completed phase 2 study tested two drug combinations—venetoclax plus obinutuzumab or venetoclax plus ibrutinib—in 20 Japanese adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see how well these combinati…

This study looked at the long-term safety and effectiveness of adalimumab (Humira) in 59 children with ulcerative colitis who had already completed a previous trial. The children received injections every other week or weekly. Researchers tracked side effects and how well the dru…

This study tested whether adding the drug venetoclax to a low-dose chemotherapy (LDAC) helps people with acute myeloid leukemia (AML) live longer. It included 211 adults aged 75+ or 18–74 with health issues that prevent them from receiving strong chemotherapy. The main goal was t…

This early-phase study tested an experimental drug called ABBV-CLS-579, given alone or with other cancer treatments, in 101 adults with advanced solid tumors that had stopped responding to standard therapy. The main goal was to find safe and tolerable doses, not to prove the drug…

This study tested an oral drug called upadacitinib (RINVOQ) against a placebo and an injected drug (adalimumab/Humira) in 1705 people with active psoriatic arthritis who had not responded well to standard non-biologic treatments. The goal was to see if upadacitinib reduces joint …

This phase 3 study tested upadacitinib, an oral anti-inflammatory drug, in 642 adults with active psoriatic arthritis who had not responded well to at least one biologic treatment. Participants received either 15 mg or 30 mg of upadacitinib daily or a placebo. The main goal was t…

This completed study followed 413 Canadian adults with moderate to severe rheumatoid arthritis who were prescribed upadacitinib by their doctors. Researchers tracked how well the drug controlled symptoms like joint pain and stiffness over 24 months. The goal was to see if the dru…

This study tested the long-term safety of a daily pill called atogepant for preventing migraines in adults with chronic or episodic migraine. Over 156 weeks, 596 participants took 60 mg of atogepant each day. Researchers tracked side effects and lab results to see if the drug rem…

This study looks at how well the migraine drug ubrogepant works in everyday life for Canadian adults. About 178 participants will take the drug as prescribed and report their ability to function normally after a migraine attack. The goal is to see if ubrogepant helps people get b…

This early-stage trial tested an investigational botulinum toxin injection called AGN-151586 for moderate to severe frown lines (glabellar lines) in 24 Japanese adults. Participants received either the active drug or a placebo, and researchers measured wrinkle improvement and saf…

This completed Phase 3 study tested an investigational botulinum toxin injection called AGN-151586 against a placebo for treating moderate to severe frown lines (glabellar lines). About 160 adults in China, Taiwan, and Japan received either the active injection or a placebo into …

This study tested whether giving an experimental drug called AGN-151586 before BOTOX is safe and effective for treating moderate to severe frown lines between the eyebrows. About 90 adults received either the experimental drug or a placebo first, then BOTOX a month later. Researc…

This study tested how well two approved migraine medications, ubrogepant (for acute attacks) and atogepant (for prevention), work together in real-world settings. 391 adults with migraine used both drugs as prescribed by their doctor for 30 days. The goal was to see if the combin…

This completed study tested how satisfied people were with their face and neck appearance after getting a combination of cosmetic treatments, including Botox, dermal fillers, a fat-reducing injection, a cooling device, and skincare products. It involved 130 participants with mode…

This study tested the drug linaclotide in children aged 2 to 5 years with functional constipation, a common condition with no approved treatments. In the first part, children received either linaclotide or a placebo for 12 weeks to see if it increased bowel movements. In the seco…

This study tested Botox (onabotulinumtoxinA) in 150 Japanese adults with moderate to severe forehead lines. Participants received injections of either Botox or a placebo and were followed for up to 12 months. The goal was to see if Botox safely reduces wrinkle severity.

This study followed 226 adults in Israel who were prescribed ubrogepant or atogepant for their migraines. Researchers wanted to see how satisfied people were with these drugs in real-world settings, not just in a lab. Participants used an app to track their experience over 90 day…

This study followed 120 adults with bipolar I disorder who were having a major depressive episode and starting cariprazine (Vraylar). Researchers measured changes in depression symptoms, daily functioning, and quality of life over 24 weeks in a real-world clinic setting. The goal…

This study tested a new botulinum toxin, AGN-151586, for treating moderate to severe frown lines between the eyebrows. About 300 adults who had never received any botulinum toxin treatment were randomly assigned to get either the study drug or a placebo. The main goal was to see …

This completed Phase 2/3 trial tested JUVÉDERM VOLITE, an injectable gel, to improve skin quality in 135 adults with fine lines and poor hydration. Participants either received the gel or no treatment, with the control group offered the gel after 2 months. The study measured aest…

This study tested whether BOTOX injections can safely reduce hand tremors in people with essential tremor, a condition that makes everyday tasks like writing or drinking difficult. About 174 adults aged 18 to 80 received either BOTOX or a placebo injection over three 12-week cycl…

This study tested an experimental drug called ABBV-932 in 161 adults with bipolar I or II disorder who were experiencing a depressive episode. Participants took either the drug or a placebo daily for 6 weeks. Researchers measured changes in depression symptoms using standard rati…

This study tested a medicine called linaclotide in 19 babies and toddlers (6 months to under 2 years old) with long-term constipation. The goal was to see if it helps them have more bowel movements and softer stools, and to check for side effects. Children took the medicine as a …

This study tested a new dermal filler called HAC 22L for improving midface volume loss in adults. About 61 participants received either the filler or delayed treatment. The goal was to see if the filler safely improves cheek fullness. Results are based on doctor ratings and patie…

This study tested whether BOTOX injections can safely reduce the size of the masseter muscle, which can make the lower face look wide. About 200 adults with noticeable muscle prominence received either BOTOX or a placebo. The goal was to see if the treatment improved appearance a…

This study tested whether BOTOX injections can safely reduce the size of the jaw muscle, making the lower face look slimmer and more oval. About 249 adults with a very prominent jaw muscle received either BOTOX or a placebo. The goal was to see if BOTOX could improve the appearan…

This study tested JUVÉDERM® VOLITE™, a gel made from hyaluronic acid and lidocaine, to safely and effectively reduce neck lines in Chinese adults. About 159 participants with moderate to severe neck lines were randomly assigned to receive the injection or no treatment. The main g…

This study tested a dermal filler called JUVÉDERM® VOLITE™ to see if it safely reduces lines around the mouth in Chinese adults. About 198 participants were randomly assigned to get the filler or no treatment. The main goal was a one-point improvement on a severity scale. Results…

This study tested how satisfied adults were with the natural look of their face after BOTOX injections for frown lines, crow's feet, and forehead wrinkles. About 100 participants received BOTOX at the start and filled out questionnaires about their satisfaction and psychological …

This early-stage study tested whether a new drug called AGN-151586 can be safely combined with BOTOX to treat moderate to severe frown lines between the eyebrows. Researchers monitored 132 healthy adults for side effects and immune responses after a single treatment session. The …

This completed Phase 3 study tested whether BOTOX injections can safely reduce the appearance of a widened lower face caused by prominent masseter (chewing) muscles. About 207 adults with moderate-to-severe muscle prominence received either BOTOX or a placebo in both sides of the…

This study tested two doses of a new drug called emraclidine (CVL-231) in 391 adults with schizophrenia who were having a sudden worsening of psychotic symptoms. Participants took the drug or a placebo daily for 6 weeks. The main goal was to see if the drug reduced symptoms like …

This Phase 2 study tested an experimental drug called ABBV-552 in 263 people with mild Alzheimer's disease. Participants took either the drug or a placebo daily for 12 weeks. The goal was to see if the drug could safely improve memory and thinking. The results will help decide if…

This Phase 2 trial tested two doses of emraclidine (10 mg and 30 mg daily) against a placebo in 385 people with schizophrenia who were having a sudden worsening of psychotic symptoms. The study lasted 6 weeks and measured symptom changes using a standard rating scale. The goal wa…

This early-stage study tested the safety and how the body processes a new drug called nacresertib in 93 healthy adults. Participants received either single or multiple doses of the drug or a placebo. The goal was to check for side effects and measure drug levels in the blood, not…

This study looked at how different versions of an experimental drug, ABBV-932, are absorbed and processed by the body. Nine healthy adults took part to measure drug levels in the blood and check for side effects. The goal was to gather information, not to treat any disease.

This study looked at the safety of the drug RINVOQ in over 4,200 Japanese adults with rheumatoid arthritis, a condition causing joint pain and swelling. Researchers reviewed medical records for three years to count serious infections and other side effects that happened during no…

This early-phase study tested a single dose of the experimental drug ABBV-142 in 73 healthy adults to check its safety and how the body handles it. The study also included a small group of Han Chinese participants to see if there are any differences. Since this is a phase 1 trial…

This early-stage trial tested the safety and how the body handles ABBV-8736 in 24 healthy adults. Participants received either the drug or a placebo through an IV. The goal was to check for side effects and measure drug levels in the blood, not to treat any disease.

This early-phase study tested a tablet form of ABBV-722 in 11 healthy adults to see how the body processes it and whether food changes its absorption. Participants took a single dose, and researchers measured drug levels in the blood and monitored for side effects. Since this is …

This study looked at how much of the drug risankizumab (Skyrizi) passes into the breast milk of women with inflammatory bowel disease (IBD). Ten breastfeeding mothers who were already taking the drug provided milk samples over several weeks. The goal is to understand potential ex…

This study tested a new questionnaire called DermCLCI-p to see if it accurately measures the long-term life impacts of moderate-to-severe psoriasis. 154 adults starting the medication risankizumab filled out the 30-question survey over 28 weeks. The goal was to validate the tool …

This study looked at the safety and effectiveness of the eczema drug upadacitinib in teenagers aged 12 to under 18 in Japan. About 170 teens who were already prescribed the drug by their doctor took part. Researchers collected data from regular clinic visits and questionnaires ov…

This study tested how well risankizumab enters the body when given through an on-body injector compared to a standard prefilled syringe. 260 healthy volunteers received the drug by one of the two methods. Researchers measured drug levels in the blood and checked for side effects …

This early-phase trial tested the safety and how the body processes a new drug called ABBV-CLS-616. It involved 110 healthy volunteers who took the drug or a placebo. The main goal was to check for side effects and understand how the drug moves through the body.

This early-stage study tested the safety and tolerability of a new drug called GUB014295 in 76 healthy adults who were lean, overweight, or obese. Participants received either the drug or a placebo as a single or multiple doses under the skin. The main goal was to check for side …

This completed Phase 1 study looked at how healthy men absorb, process, and eliminate a single oral dose of ABBV-1354 (Icalcaprant). Eight participants were monitored for side effects, vital signs, and drug levels in blood, urine, and feces. The goal was to understand the drug's …

This early-stage study tested the safety and how the body processes ABBV-932, an experimental oral drug, in 20 healthy Chinese adults. Participants received multiple doses to check for side effects and measure drug levels in the blood. Since this is a Phase 1 trial in healthy vol…

This completed Phase 1 study tested how well the drug risankizumab (SKYRIZI) enters the body when given by a prefilled pen compared to a prefilled syringe. Fifty-nine healthy adults received a single injection, and researchers measured drug levels and side effects. The goal was t…

This completed study in Japan looked at 89 adults with relapsed chronic lymphocytic leukemia (CLL) who took Venetoclax (with or without Rituximab) for 24 months. The main goal was to see how many had undetectable minimal residual disease (uMRD), a sign of deep response. Researche…

This completed Phase 1 study tested how well the drug risankizumab (SKYRIZI) is absorbed when given through an on-body injector compared to a standard injection. It involved 263 healthy adults and measured drug levels in the blood and any side effects. The goal was to see if the …

This study looked at how vitiligo affects people in China, including their treatments and daily life. Researchers observed 100 patients to measure the disease's impact on their skin and quality of life. The goal was to better understand the real-world burden of this condition.

This study looked at how a new tablet form of the drug venetoclax is absorbed in the body. 72 healthy women took the drug under different conditions (with or without high-fat food) to measure drug levels and side effects. The goal was to gather information, not to treat any disea…

This study looked at how a high-fat meal changes the way ABBV-101 moves through the body. Seventeen healthy adults took the drug with or without food. The goal was to measure safety and drug levels in the blood, not to treat any disease.

This study followed 240 adults in Taiwan with moderate-to-severe plaque psoriasis to see how well risankizumab works compared to other biologics in real-world settings. Participants received their prescribed treatment and were monitored for about 2 years. The main goal was to mea…